Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Mixed phenotype (MP) in acute leukemia presents classification and management challenges.
• Distinguishing between acute myeloid leukemia with MP (AML-MP) and MPAL is crucial for effective treatment.

Purpose of the Study:

• To define AML-MP and MPAL as distinct groups.
• To characterize their clinical, genetic, and transcriptomic features.
• To provide insights into pathogenesis and therapy.

Main Methods:

• Analysis of a large cohort of acute leukemia with MP.
• Characterization of clinical, genetic, and transcriptomic features.
• Comparison of treatment responses and outcomes.

Main Results:

• AML-MP demonstrated inferior response to induction regimens compared to MPAL.
• AML-MP exhibited distinct genetic profiles with frequent RUNX1 and TP53 mutations.
• Transcriptomic analysis revealed stemness enrichment and a deficit in differentiation factors in AML-MP.
• AML-MP rarely switched to a lymphoid immunophenotype post-treatment, unlike MPAL.

Conclusions:

• AML-MP should be designated as a distinct diagnosis separate from MPAL.
• Novel insights into the pathogenesis and therapeutic strategies for acute leukemia with MP were provided.
• A genomic classification framework for future studies was proposed.